Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
Monsanto legal cases Columbia, thereby indicating that Monsanto had complied fully with the terms of the agreement. In 2014, Monsanto reached a settlement with soft wheat farmers over the 2013 discovery of experimental glyphosate-resistant wheat in a field in Oregon which had led to South Korea and Japan temporarily stopping some US wheat importation. The settlement included the establishment of a $2.125 million fund for economically affected soft-wheat farmers. In 2003, Monsanto sued Oakhurst Dairy over Oakhurst's label on its milk cartons that said "Our farmer's pledge: no artificial hormones," referring to the use of bovine somatotropin (rBST). Monsanto argued that the label